Rezolute Inc 2025年季度报告

Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d)of the Securities Exchange Act of1934 during the preceding 12months (or for such shorter period that the registrant was required to file such reports), and (2)has been subject tosuch filing requirements for the past 90days.☒Yes☐No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submitsuch files.).☒Yes☐No Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company,and an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerginggrowth company” in Rule12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section17(a)(2)(B)of the Securities Act.☐ Indicate by check mark whether the Registrant is a shell company (as defined in Rule12b-2 of the Exchange Act)☐Yes☒No The registrant had92,727,532shares of its $0.001 par value common stock outstanding as of November 4, 2025. Table of Contents Item 1. Financial StatementsUnaudited Condensed Consolidated Balance Sheets – as of September 30, 2025 and June 30, 20251Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss – Three MonthsEnded September 30, 2025 and 20242Unaudited Condensed Consolidated Statements of Shareholders’ Equity – Three Months Ended September30, 2025 and 20243Unaudited Condensed Consolidated Statements of Cash Flows – Three Months Ended September 30, 2025and 20244Notes to Unaudited Condensed Consolidated Financial Statements5Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations20Item 3. Quantitative and Qualitative Disclosures About Market Risk28Item 4. Controls and Procedures28 Item 1. Legal Proceedings29Item 1A. Risk Factors29Item 2. Unregistered Sales of Equity Securities and Use of Proceeds29Item 3. Defaults Upon Senior Securities29Item 4. Mine Safety Disclosures29Item 5. Other Information29Item 6. Exhibits29 Signatures30 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2025 (the “Report”) containsstatements reflecting assumptions, expectations, projections, intentions or beliefs about future events that are intendedas “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Allstatements included or incorporated by reference in this Report, other than statements of historical fact, that addressactivities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements appear in a number of places, including, but not limited to “Management’sDiscussion and Analysis of Financial Condition and Results of Operations.” These statements represent our reasonablejudgment of the future based on various factors and using numerous assumptions and are subject to known andunknown risks, uncertainties and other factors that could cause our actual results and financial position to differmaterially from those contemplated by the statements. You can identify these statements by the fact that they do notrelate strictly to historical or current facts, and use words such as “anticipate”, “believe”, “estimate”, “expect”,“forecast”, “may”, “should”, “plan”, “project” and other words of similar meaning. In particular, these include, but arenot limited to, statements relating to the following: ●our ability to obtain regulatory approvals for our therapeutics in development;●our expectations regarding clinical development and the timeline to complete clinical studies;●our projected operating or financial results, including anticipated cash flows to be used in operating activities;●our expectations regarding capital expenditures, research and development (“R&D”) expenses and the timingof milestone payments required under license agreements;●our beliefs and assumptions relating to our liquidity position, including our ability to obtain additionalfinancing;●ourfuture dependence on third-party manufacturers or strategic partners to manufacture any of ourpharmaceutical drugs and diagnostics that receive regulatory approval; and●our ability to identify strategic partners and enter into license, co-development, collaboration or similararrangements. Any or all of our forward-looking statements may turn out to be wrong. They can be affe